Join to View Full Profile
800 Howard AveYale Physicians Building 2ND floorNew Haven, CT 06519
Phone+1 203-688-4191
Fax+1 203-737-2617
Dr. DiGiovanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael DiGiovanna, MD/PhD, is an oncology specialist located in New Haven, CT, with a subspecialty focus on breast cancer. He completed his medical education and training at Yale, including a residency in Internal Medicine and a fellowship in Medical Oncology. Serving as a Professor at Yale Medical School and attending at Yale New-Haven Hospital/Smilow Cancer Hospital since 1997, Dr. DiGiovanna has extensive experience in treating breast cancer and has contributed significantly to the field through numerous publications, notably in high-impact journals such as The New England Journal of Medicine and the Journal of Clinical Oncology. He has also been involved in numerous breast cancer clinical trials.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1997- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1993
Yale School of MedicineClass of 1990
Certifications & Licensure
CT State Medical License 1993 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
Publications & Presentations
PubMed
- PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence.Haiying Zhan, Vijay Mariadas Antony, Haiming Tang, Janie Theriot, Yuanxin Liang
Breast Cancer Research and Treatment. 2025-06-01 - 2 citationsTrends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017.Michal Marczyk, Adriana Kahn, Andrea Silber, Mariya Rosenblit, Michael P Digiovanna
Journal of the National Cancer Institute. 2025-02-01 - 5 citationsSurvival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.Charles E Geyer Jr, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas
The New England Journal of Medicine. 2025-01-16
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
